Evidence map›Paper›PMID 42315253›Full record

ArticleJournal for immunotherapy of cancer2026

Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy.

Félix K Pham, Marion Dufeu, Valentin Benboubker, Maxime Grimont, Amélie Lhorisson, Justine Berthet, Marie Donzel, Raphaël Schneider, Laurie Tonon, Anne-Claire Doffin and 9 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03225365 (Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03225365 nacompletednot on this map

Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1).

TypeinterventionalSponsorHospices Civils de LyonRan2019 to 2021Enrolled5ConditionsMetastatic MelanomaArmsBlood and biopsy sampling
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Félix K Pham *"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-7855-4930
Marion Dufeu *"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Valentin Benboubker"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Maxime Grimont"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Amélie LhorissonINSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Justine BerthetINSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Marie DonzelPathology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.
Raphaël SchneiderPlateforme de bio-informatique Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Fondation Synergie Lyon Cancer, Lyon, France.
Laurie TononPlateforme de bio-informatique Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Fondation Synergie Lyon Cancer, Lyon, France.
Anne-Claire DoffinINSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Félix Boivin"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Simon Durand"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Bertrand DuboisINSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Jonathan Lopez"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Christophe CauxINSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Jenny Valladeau-GuilemondINSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Cancérologie de Lyon, Lyon, France.ORCID http://orcid.org/0000-0003-4160-8867
Anaïs Eberhardt"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Stéphane Dalle"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Julie Caramel"Cancer cell Plasticity in Melanoma" lab, "Equipe labellisée Ligue Contre le Cancer", INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, Centre de Recherche en Cancérologie de Lyon, Lyon, France julie.caramel@lyon.unicancer.fr.ORCID http://orcid.org/0000-0002-8883-918X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelanoma shows one of the highest response rates to immune checkpoint inhibitors (ICIs), yet nearly half of patients experience primary or acquired resistance. While immune contexture strongly influences therapeutic efficacy, tumor cell-intrinsic features are increasingly recognized as key regulators of antitumor immunity. In particular, intratumoral heterogeneity driven by melanoma cell plasticity underlies diverse immune escape mechanisms. How this plasticity shapes ICI outcomes in patients remains poorly defined.

methodsTumor cell states and immune contexture were assessed in 57 primary cutaneous melanomas from stage III patients, collected prior to adjuvant anti-programmed cell death protein-1 (anti-PD-1) therapy and stratified according to 2-year relapse status (33 relapse-free, 24 relapsed). Whole slide multiplex immunofluorescence was combined with spatial transcriptomics (Visium, n=4) to investigate the spatial architecture of melanoma cell states, T cells, tumor-associated macrophages (TAMs), dendritic cell subsets, and tertiary lymphoid structures.

resultsUnsupervised clustering of melanoma cells identified distinct phenotypic states that formed spatially restricted homotypic patches. From these data, we defined a melanoma plasticity ratio (undifferentiated/differentiated tumor patches), which was significantly associated with reduced relapse-free survival. Integrated immune analyses recapitulated prognostically distinct immunotypes, with macrophage subsets displaying striking spatial compartmentalization. Antitumoral macrophages preferentially infiltrated differentiated melanoma regions, while protumoral macrophages localized to undifferentiated patches. Spatial transcriptomics confirmed that melanoma cell states tightly shape the neighboring immune microenvironment, with macrophages emerging as pivotal players. Their polarization was further influenced by tumor-derived signals in addition to microenvironmental cues (interferon-gamma, hypoxia). Entropy-based integration of melanoma cell states, TAMs, and T cell subsets uncovered two dominant spatial ecosystems with opposing associations to ICI efficacy. Ecosystems enriched in differentiated melanoma cells, programmed death-ligand 1 (PD-L1)

conclusionsOur study uncovers how cancer cell plasticity shapes spatially organized tumor-immune ecosystems that critically modulate adjuvant ICI efficacy in melanoma. These findings highlight melanoma cell plasticity as a key driver of immune evasion via macrophages reprogramming, through targetable interactions that may represent novel therapeutic avenues to enhance ICI efficacy.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyMelanomaProgrammed Cell Death 1 ReceptorSkin NeoplasmsTumor MicroenvironmentFemaleHumansSpatial TranscriptomicsImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorComputational BiologyImmune Checkpoint InhibitorsMacrophagesMelanomaTumor Microenvironment

Identifiers

PMID42315253
PMCPMC13289303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.